Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease.
Gaucher disease
enzyme replacement therapy
monoclonal gammopathy of unknown significance (MGUS)
multiple myeloma
polyclonal gammopathy
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
11
12
2021
received:
01
09
2021
accepted:
11
12
2021
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
14
5
2022
Statut:
ppublish
Résumé
Patients with Gaucher disease (GD) have been shown previously to carry an increased risk for cancer, most commonly multiple myeloma (MM). It is currently unknown whether treatment for GD has an effect on the prevention or amelioration of MM. We present the case of a 41-year-old patient simultaneously diagnosed with GD and smouldering MM. Enzyme replacement therapy with Velaglucerase-alfa significantly improved myeloma indices.
Substances chimiques
Glucosylceramidase
EC 3.2.1.45
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-875Informations de copyright
© 2022 Royal Australasian College of Physicians.
Références
Arends M, van Dussen L, Biegstraaten M, Hollak CEM. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 2013; 161: 832-42.
Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 1993; 72: 219-24.
Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 2005; 34: 197-200.
de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36: 53-8.
Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009; 84: 208-14.
Zimran A, Ruchlemer R, Revel-Vilk S. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. Hematology Am Soc Hematol Educ Program 2020; 2020: 389-94.
Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105: 4569-72.
Revel-Vilk S, Szer J, Zimran A. Hematological manifestations and complications of Gaucher disease. Expert Rev Hematol 2021; 14: 347-54.
de Fost M, Out TA, de Wilde FA, Tjin EPM, Pals ST, van Oers MHJ et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008; 87: 439-49.
Grosbois B, Rose C, Noël E, Serratrice C d R, Dobbelaere D, Gressin V et al. Gaucher disease and monoclonal gammopathy: a report of 17 cases and impact of therapy. Blood Cells Mol Dis 2009; 43: 138-9.
Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 2004; 32: 214-17.
Nguyen Y, Stirnemann J, Lautredoux F, Cador B, Bengherbia M, Yousfi K et al. Immunoglobulin abnormalities in Gaucher disease: an analysis of 278 patients included in the French Gaucher disease registry. Int J Mol Sci 2020; 21: 1247. doi:10.3390/ijms21041247
Wątek M, Piktel E, Wollny T, Durnaś B, Fiedoruk K, Lech-Marańda E et al. Defective sphingolipids metabolism and tumor associated macrophages as the possible links between Gaucher disease and blood cancer development. Int J Mol Sci 2019; 20: 843. doi:10.3390/ijms20040843
Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol Genet Metab 2020; 129: 286-91.
Preuss K-D, Hollak CEM, Fadle N, van Oers M, Regitz E, Pfreundschuh M. Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma. Br J Haematol 2019; 184: 384-91.
Revel-Vilk S, Szer J, Mehta A, Zimran A. How we manage Gaucher disease in the era of choices. Br J Haematol 2018; 182: 467-80.
Wine E, Yaniv I, Cohen IJ. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. J Pediatr Hematol Oncol 2007; 29: 451-7.
Martinez-Redondo C, Ortuño FJ, Lozano ML, Jerez A, del Mar OM, Giraldo P et al. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report. J Inherit Metab Dis 2009; 32: S265-7.
Camou F, Viallard J-F. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy. Blood Cells Mol Dis 2012; 48: 51-2.
Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol 2015; 235: 113-24.